Materials and Methods
|
|
- Ethelbert Berry
- 6 years ago
- Views:
Transcription
1 Peripheral Blood Morphologic Changes after High-Dose Antineoplastic Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Administration DANIEL P. KERRIGAN, M.D., ANNIE CASTILLO, M.D., KATHY FOUCAR, M.D., KELLY TOWNSEND, MT(ASCP), AND JAMES NEIDHART, M.D. The peripheral blood morphologic findings in 17 patients with cancer who had received high-dose cytotoxic chemotherapy followed by recombinant human-granulocyte colony-stimulating factor (rh-gcsf) were reviewed and compared with a control group of patients who received only high-dose chemotherapy. Both groups showed dysmyelopoiesis (abnormal granulation and nuclear lobulation) in the granulocytic series during the period of bone marrow recovery that followed the cytotoxic chemotherapy. Most of these morphologic abnormalities were more prominent in the rh-gcsf-treated group. Monocytic cells in both groups showed prominent vacuolation and immature nuclei. The percentages and absolute numbers of large granular lymphocytes were increased in the rh-gcsf group compared with the control group. No quantitative or qualitative abnormalities of eosinophilic or basophilic granulocytes were detected in either group. Both groups showed nonspecific red blood cell abnormalities, and large platelets were present in half of the control group smears. This report provides the first detailed peripheral blood morphologic description in patients treated with rh-gcsf and high-dose chemotherapy. (Key words: GCSF cytotoxic therapy; WBC morphology) Am J Clin Pathol 1989;92: A DOSE-LIMITING FACTOR in the treatment of human malignancies is neutropenia because of its association with increased risk of infection. 6 The neutropenia results from the direct toxic effects of antineoplastic therapy on granulocyte precursors in the bone marrow. 2 Therapy aimed at reducing this side effect has tremendous potential for decreasing morbidity and mortality in patients with cancer. One approach that has been proposed to counteract chemotherapy-induced myelosuppression is administration of hematopoietic growth factors. 3 A number of hematopoietic growth factors have recently been identified, sequenced, biosynthesized, and used in a variety of in vitro and in vivo studies. 3 One of these factors, recombinant human-granulocyte colony-stimulating factor (rh- GCSF), has been shown to primarily stimulate the production and enhance the function of granulocytes."" 13 Recent clinical trials using rh-gcsf have shown a significant decrease in neutropenia-associated complications Received October 27, 1988; received revised manuscript and accepted for publication January 30, Address reprint requests to Dr. Kerrigan: Department of Pathology, University of New Mexico, Albuquerque, New Mexico Departments of Pathology and Hematology/Oncology, University of New Mexico, Albuquerque, New Mexico when it has been given to cancer patients also receiving antineoplastic chemotherapy. 5,8 ' 9 This simultaneous and/ or sequential exposure of the bone marrow to a potent hematopoietic growth factor(s) and a potent toxin(s) was previously seen only in chemotherapy-treated patients with tumors producing endogenous hematopoietic growth factors. 10 The peripheral blood morphologic characteristics in this unique setting have been described only briefly. 8 In this article, we present a detailed description of sequential peripheral blood hemogram data and morphologic characteristics from 17 patients who received both high-dose chemotherapy and rh-gcsf. The relationship of these findings to the sequential bone marrow exposure to potent toxins and growth factors is discussed. Materials and Methods Sequential peripheral blood samples from 17 patients (10 male/7 female), ranging in age from 26 to 64 years, who were treated with rh-gcsf and high-dose cytotoxic chemotherapy for a variety of malignancies (10 carcinomas, 5 lymphomas, 1 melanoma, and 1 sarcoma), constitute this study. Fifteen of the 17 had received prior radiation and/or chemotherapy. The cytotoxic chemotherapy, consisting of cyclophosphamide ( g/m 2 ), etoposide ( mg/m 2 ), and cisplatinum (35-60 mg/ m 2 ), was administered during the time period shown in Figure 1. Decadron was given as an antiemetic during the first three days of treatment. Recombinant human- GCSF was given in doses of 20, 40, or 60 /tg/(kg day). The clinical and therapeutic details of a larger group of patients that included these 17 are reported elsewhere. 9 Eleven patients in this series received more than one cycle containing rh-gcsf (7 received two cycles and 2 received three cycles). Peripheral smears from nine high-dose chemotherapy cycles in seven patients who did not receive rh-gcsf were also reviewed. These findings were com- 280
2 Vol. 92 No. 3 GCSF AND CYTOTOXIC THERAPY EFFECTS ON WBCs 1000 E 281 FIG. 1. Individual patient total WBC count during an rh-gcsf-containing treatment cycle. Patientreceived60 /ig/kg/day of rh-gcsf. 100 WBC xiovi 10 '_ Cytotoxlo Chemotherapy rh-gcsf Day of Cycle pared with the rh-gcsf-containing cycles to determine which morphologicfindingswere attributable to addition of rh-gcsf to the therapy protocol. Coulter S+IV (Coulter Electronics, Hialeah, FL) results, including white blood cell (WBC) count, platelet count, hematocrit, hemoglobin, mean corpuscular volume (MCV), MCHC, MCH, and red blood cell distribution width (RDW) were obtained daily on the patients' peripheral blood drawn in the morning. One hundred-cell differential counts were performed daily by technologists on Wright's-stained peripheral blood smears that generally were made within two hours of drawing the patient's blood. Peripheral smears from the day with the peak WBC count during the rh-gcsf administration were selected for more detailed morphologic review, and 200-cell differential counts were performed on these smears by one of the authors (D.P.K.). For patients who did not receive rh-gcsf, the peripheral smear from the day with the highest WBC count between days 7 and 28 was reviewed. In addition to differential counts, the presence and/or degree of toxic granulation, Dohle bodies, monocyte vaciiolation, dyspoietic changes, 1 large granular lymphocytes (LGLs), and red blood cell (RBC) and platelet abnormalities were noted on each blood smear. Results The most common pattern of WBC, granulocyte, lymphocyte, and monocyte fluctuation for patients receiving high-dose chemotherapy followed by rh-gcsf rescue is WBC xio*vi Granulocytes lymphocytes Monocytes -B- Immature Myeloid FIG. 2. Absolute cell counts for the cell cycle shown in Figure Day of Cycle
3 282 KERRIGAN ET AL. A.J.C.P.-September monocytes promyelocytes/blasts \m\ meta/myelocytes EH3 lymphocytes 20 - % of total WBQ ^ I 1 I I m I I i I i 1 p I M PK DAY PK DAY PK DAY Day Of PK DAY PK DAY PK DAY -e -4-2 peak WBC *z *4 +e FIG. 3. WBC percentages before and after the peak WBC count observed during rh-gcsf therapy. Median values for the 25 cycles with leukocytosis. (Band and segemented neutrophils account for the remaining cell percentages.) shown in Figures 2 and 3. Three discrete WBC peaks and one period of neutropenia were seen. ThefirstWBC peak occurred during administration of Decadron and resulted from an increase in segmented neutrophils. A second smaller transient increase in WBC count was observed on day 7 in 70% of cycles. It occurred within 24 hours of the initial dose of rh-gcsf, lasted less than 48 hours, and went as high as 7 X 10 9 /L. This peak was composed of band and segmented neutrophils and was more common and pronounced in patients who had received rh-gcsf in prior cycles. This brief WBC elevation was followed by a period of profound neutropenia (granulocytes usually <0.1 X 10 9 /L) that lasted for 5-19 days (median, 9 days). In most patients, a brisk neutrophilia and monocytosis followed this period of neutropenia, developing between 18 and 28 days (median, 25 days) after the initiation of chemotherapy. The peak WBC during this period exceeded normal limits (10 X 10 9 /L) in 25 of 35 (78%) treatment cycles in which rh-gcsf therapy was administered. In contrast, the WBC count in patients treated with highdose chemotherapy alone never exceeded 10 X 10 9 /L, and no prominent WBC count peaks were seen. Patients who received the highest doses of rh-gcsf (60 /ug/kg/ day) had the most striking WBC responses. Peripheral Blood Morphology Band and Segmented Neutrophils (PMNs). Differential counts from the peak WBC count day during rh-gcsf treatment showed that most (>80%) of the WBCs were band or segmented neutrophils (Fig. 3). The median peak neutrophil count was 30 X 10 9 /L for the 32 cycles containing rh-gcsf. In every cycle in which rh-gcsf was administered,-including cycles in which the maximum WBC count was less than 10 X 10 9 /L, at least 25% of the bands and segmented neutrophils contained toxic granules and/or Dohle bodies. These changes were seen with similiar frequency in patients receiving all three dose levels of rh-gcsf. The number of toxic granules and Dohle bodies per neutrophil varied widely, but all smears contained easily identifiable cells with large numbers of both. In addition, cells in which most of the neutrophil cytoplasm remained moderately basophilic without distinct Dohle bodies were seen in smears with the most striking Dohle bodies. In contrast, hypogranular neutrophils were also present in about half the cases, generally accounting for less than 25% of the cells, although these cells predominated in one patient's smear. In some cases a combination of hypogranularity and Dohle bodies was present in the same cell (Fig. 4A). Neutrophils with increased diameter were also identified easily. Nuclear lobulation of granulocytes was abnormal in all cases with both hypersegmentation and hyposegmentation (Figs. 4B-D). In most smears at least 25% of the nuclei exhibited easily recognizable nuclear abnormalities. Nuclei with five or more lobes, psuedo-pelger-huet nuclei, and corkscrewshaped nuclei were the most common abnormalities, whereas circular nuclei were also seen (Figs. 4E and F). Slides from the bone marrow recovery period in the non-rh-gcsf cycles (days 17-34) showed many of the same findings as the rh-gcsf smears (Table 1), but in general the findings were seen in fewer cells and were much less prominent when present. Exceptions to this
4 Vol. 92 No. 3 GCSF AND CYTOTOXIC THERAPY EFFECTS ON WBCs 283 FlG. 4 (left). Peripheral blood granulocyte morphologic characteristics after high-dose cytotoxic chemotherapy and rh-gcsf. A. Hypogranular cytoplasm with Dohle bodies (arrows). B. Hyperlobulated nucleus. C. Hypolobulated nucleus. D. Circular nucleus. E. Convoluted "corkscrew" nucleus. F. Hypolobulated nucleus. Wright (X 1,000). FIG. 5 (right). Peripheral blood leukocyte morphologic characteristics after high-dose cytotoxic chemotherapy and rh-gcsf. A. Immature myeloid cell with blast-stage nuclear myelocytic-stage cytoplasmic maturation. B. Vacuolated monocyte. C. Mature and immature monocytoid cells. D. Lymphocyte with abnormal nuclear lobulation. E. Myeloid cell fragment. Wright (X 1,000). included hypogranular PMNs with Dohle bodies and hyperlobulated PMNs that were seen only in patients receiving rh-gcsf. The differential counts in these nonrh-gcsf cycles showed a lower percentage of granulocytes compared with the rh-gcsf-containing cycles (median percentages, 53% vs. 85% band plus segmented neutrophils, respectively). Immature Myeloid Cells (blasts through metamyelocytes). Immature myeloid cells averaged 2-10% of the WBC count during the rh-gcsf-induced peak WBC count period (Fig. 3). The highest absolute numbers of these immature cells occurred simultaneously with the peak WBC (Fig. 2). Myelocytes and metamyelocytes were more numerous than blasts and promyelocytes (Fig. 3). The percentages of immature myeloid cells appeared to be independent of the total WBC count. The highest absolute immature myeloid cell count was 35 X 10 9 /L. In cycles not containing rh-gcsf, the percentage, but not absolute number, of immature cells was slightly higher (median, 12.5%) during this period, with a much wider range (0.5-36%). Similar to the rh-gcsf-treated group, the meta/myelocytes outnumbered the promyelocytes/ blasts. The highest absolute immature myeloid cell count was 2.1 X 10 9 /L. Immature cells gradually disappeared from the blood as the WBC count returned to normal in both groups (Fig. 3). Dysynchrony between nuclear and cytoplasmic maturation was easily identified in most smears of the rh- GCSF-treated group. The predominant abnormality was a chromatin pattern and nuclear shape that was less differentiated than the cytoplasm (Fig. 5^4). In addition, very intense staining of the primary granules was seen in promyelocytes. Similar abnormalities were seen in the cycles not containing rh-gcsf, but they were less striking than in the rh-gcsf-containing cycles. Monocytes. The fluctuations in monocyte counts in patients receiving rh-gcsf closely resembled those of the granulocytes, and 22 of the 24 monocyte peaks occurred within 48 hours of the peak granulocyte count. Peak absolute monocyte counts ranged from 0.1 to 14 X 10 9 /L (median, 3.7 X 10 9 /L), and monocytes exceeded 1.0 X 10 9 /L in 24 of 35 rh-gcsf-containing cycles. The monocyte morphologic characteristics were remarkable for consistent prominent vacuolation in every case (Fig. 5B), even if an absolute monocytosis was not present. In addition, immature monocytes with moderately increased nuclear/cytoplasmic ratios, a fine chromatin pattern, and prominent nucleoli were seen in two-thirds of the cycles (Fig. 5C). The chemotherapy cycles lacking rh-gcsf showed identical morphologic findings in the monocytes. The absolute number of monocytes, however, was increased in only one of nine cycles. Lymphocytes. In rh-gcsf-treated patients, lymphocyte morphologic characteristics were generally unremarkable, although the proportion of large granular lym-
5 284 KERRIGAN ET AL. A.J.C.P. September 1989 Table 1. Peripheral Blood Morphologic Findings after High-Dose Chemotherapy With and Without rh-gcsf identified in patients receiving only high-dose chemotherapy. Peripheral Blood Morphologic Findings During Bone Marrow Recovery Toxic granulationf Dohle bodiesf Abnormal myeloid nuclear lobulation! Hypogranular PMNs present Percentage neutrophils >80% Vacuolated monocytes! Large granular lymphocytes (> 50% of lymphs) Immature monocytes (>1% of cells) Large platelets Myeloid cell fragments Immature forms of undetermined lineage (>1% of cells) Plasmacytoid lymphocytes (>1%) High-Dose Chemotherapy Cycles With rh-gcsf* 84% (both hyperlobulated and hypolobulated) 55% 66% 66% 5% Occasional 60% 12% * Percentage of cycles in which morphologic abnormality detected. t Findings were present in 25% or more of appropriate cells. Without rh-gcsf* 55% 22% 33% (hypolobulated only) Rare 22% 0 22% 77% 55% 66% 44% phocytes (LGLs) was greatly increased (>50% of lymphocytes) in two-thirds of these cases and the absolute number of large granular lymphocytes exceeded 1.0 X 10 9 / L in one-third of cases. In addition, lymphocytes with clover leaf and other nuclear abnormalities were seen on two smears. One of these patients was being treated for lymphoma and one for carcinoma (Fig. 5D). Two patients with carcinoma had small numbers (1-5%) of plasmacytic/immunoblastic lymphocytes with normal nuclear contours. Mildly elevated lymphocyte counts ( X 10 9 /L) occurred within 24 hours of the peak WBC count in 24% of cycles with leukocytosis and in no cycle without leukocytosis. Review of smears from non-rh-gcsf-containing cycles showed an increased percentage of large granular lymphocytes in 22% of cases, but the absolute number of these cells never exceeded 1.0 X 10 9 /L. Abnormal lymphoid nuclear lobulation was seen in one cycle. Fortyfour percent of these cycles had 1% or more plasmacytoid/ immunoblastic lymphocytes, and in one case the cells contained Dutcher bodies. No lymphocyte elevations were Other Features Two additional abnormal features (cytoplasmic fragments and immature cells of undetermined lineage) were noted. The cytoplasmic fragments (ranging up to 15 nm in diameter) were seen in several smears from cases with WBC counts greater than 100 X 10 9 /L (Fig. 5E). The fragments had a faintly basophilic cytoplasm and varying numbers of strongly azurophilic granules. These fragments closely resembled the cytoplasm of immature granulocytic cells in the same smears. The immature cells of undetermined lineage were seen in half of the cases, always accounted for 5% or less of the cells, and tended to be more frequent in patients with higher WBC counts. They were similar in size, nuclear to cytoplasmic ratio, and chromatin pattern to promyelocytes but lacked primary granules. Some had partially indented nuclei, similar to an immature monocyte. The cytoplasm of these cells was faintly to moderately basophilic and occasionally contained vacuoles. These fragments and cells were seen in cycles with and without rh-gcsf but were more common in the rh-gcsf-containing cycles. Eosinophils and basophils always accounted for less than 1% of cells, and no morphologic abnormalities were noted. Except for one case that showed prominent basophilic stippling, red blood cell morphologic changes were limited to mild to moderate nonspecific anisopoikilocytosis, mild polychromasia, and occasional (<2 per 100 WBCs) nucleated red blood cells. Abnormal platelet morphologic characteristics were limited to hypogranular platelets in one rh-gcsf-treated patient and large platelets (>7 ^m diameter) in half of the control group patients. Discussion Granulocyte colony-stimulating factor and other hematopoietic growth factors have recently become available in purified form through the efforts ofscientists in a variety of fields. 3 DNA cloning of the human GCSF gene, accomplished in 1986, has allowed production of sufficient GCSF for a variety of in vitro and, more recently, in vivo studies of its effect on hematopoiesis. 5 The preliminary in vitro and in vivo data have shown that GCSF is a potent stimulator of granulocyte function and production. It has also been shown to reduce cytotoxic chemotherapy-associated complications in humans. 5,813 This is the first study to provide a detailed description of the peripheral blood morphologic characteristics in patients receiving intensive therapy with antineoplastic chemotherapy followed by rh-gcsf. The morphologic
6 Vol. 92 No. 3 GCSF AND CYTOTOXIC THERAPY EFFECTS ON WBCs 285 changes seen in these cases reflect the combined effects of the antineoplastic drugs and a potent hematopoietic growth factor (rh-gcsf). We suggest the morphologic changes attributable to rh-gcsf administration are the hyperlobulated PMNs and the increased toxic granulation and Dohle bodies in neutrophils. 8 Myelodysplastic changes, including abnormal nuclear lobulation, hypogranular cytoplasm, and nuclear-cytoplasmic maturation dysynchrony, are well described after antineoplastic therapy, 4 and the antineoplastic therapy probably accounts for most of these findings in our cases. It is the combination of these findings (along with the significant leukocytosis) in both a single patient and within a single cell that seems unique to this patient population. The more pronounced myelodysplastic changes in the rh-gcsftreated patients suggests that rh-gcsf stimulated myeloid cell proliferation and maturation is occurring at a point when the marrow has not recovered from the cytotoxic chemotherapy injury. The cause of the additional peripheral blood abnormalities, including monocyte vacuolation, WBC fragmentation, increased absolute numbers of large granular and/or plasmacytoid lymphocytes, and occasional abnormal lymphocyte nuclear lobulation, is uncertain. The immunophenotypic and functional characteristics of the LGLs may be of clinical interest because tumor-killing lymphocytes can morphologically be LGLs. It may also be interesting to examine molecular and/ or cytogenetic events associated with the striking morphologic changes seen in this setting because many of these abnormalities are those seen in myelodysplastic syndromes 4 and chemotherapy-related leukemias. 7 Acknowledgments. The authors thank L. Sousa, Ph.D., and M. Downing, Ph.D., of AMGEN Corporation of Thousand Oaks, California, for reviewing the manuscript and supplying the rh-gcsf used in this study. References 1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51: Brunning RD. The effects of leukemia and lymphoma chemotherapy on hematopoietic cells. Am J Med Technol 1973;39: Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987;236: Foucar K., McKenna R, Bloomfield C, et al. Therapy related leukemia, a panmyelosis. Cancer 1979;43: Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318: Hoagland HC. Hematologic complications of cancer chemotherapy. Semin Oncol 1982;9: Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987;14: Morstyn G, Souza L, Keech J, et al. Effect of granulocyte colony stimulating factor on neutropenia induced cytotoxic chemotherapy. Lancet 1988;1: Neidhart J, Kohler B, Castillo A, et al. Recombinant human granulocyte-colony stimulating factor (rhg-csf) shortens duration of granulocytopenia and thrombocytopenia following intensive chemotherapy dosing. (Submitted for publication). 10. Robinson WA. Granulocytosis in neoplasia. Ann NY Acad Sci 1974;230: Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte-colony stimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232: Welte K, Bonilla MA, Gabrilove JL, et al. Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesis. Blood Cells 1978;13: Yuo A, Kitagawa S, Okabe T, et al. Recombinant human granulocyte-colony stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 1987;70:
Blood Cell Identification Graded
BCP-21 Blood Cell Identification Graded Case History The patient is a 37-year-old female with a history of multiple sickle cell crises. She now presents with avascular necrosis of the left hip. Laboratory
More informationEDUCATIONAL COMMENTARY DIFFERENTIATING IMMATURE PERIPHERAL BLOOD CELLS
Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Continuing Education on the left side of the
More informationParticipants Identification No. % Evaluation. Mitotic figure Educational Erythrocyte precursor, abnormal/
Cell Identification BMD-09 Participants Identification No. % Evaluation Mitotic figure 233 96.7 Educational Erythrocyte precursor, abnormal/ 4 1.7 Educational dysplastic nuclear features Erythrocyte precursor
More informationNEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TEST PROGRAM Glass Slide - November 2016
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TEST PROGRAM Glass Slide - November 2016 Results from this proficiency test event are available at: http://www.wadsworth.org/regulatory/clep/pt/summaries SLIDE
More informationVETERINARY HEMATOLOGY ATLAS OF COMMON DOMESTIC AND NON-DOMESTIC SPECIES COPYRIGHTED MATERIAL SECOND EDITION
VETERINARY HEMATOLOGY ATLAS OF COMMON DOMESTIC AND NON-DOMESTIC SPECIES SECOND EDITION COPYRIGHTED MATERIAL CHAPTER ONE HEMATOPOIESIS GENERAL FEATURES All blood cells have a finite life span, but in normal
More informationParticipants Identification No. % Evaluation. Mitotic figure Educational Erythrocyte precursor, abnormal 1 0.
Cell Identification Mitotic figure 212 99.5 Educational Erythrocyte precursor, abnormal BMD-02 The arrowed cell is a mitotic figure. It was correctly identified by 99.5% of the participants. A cell containing
More informationBlood Cell Identification Graded
Blood Cell Identification Graded Case History The patient was a five-day-old girl with an elevated unconjugated bilirubin and a weakly positive direct antiglobulin test (DAT). Her CBC showed: WBC = 11.0
More informationBlood Cell Identification Graded
Blood Cell Identification Graded BCK/BCP-11 BCK BCP Referees Participants Participants Performance Identification No. % No. % No. % Evaluation Neutrophil, segmented or band Neutrophil with Pelger-Huët
More informationBy Dr. Mohamed Saad Daoud
By Dr. Mohamed Saad Daoud Part I Introduction Types of White Blood Cells Genesis of the White Blood Cells Life Span of the White Blood Cells Dr. Mohamed Saad Daoud 2 Leucocytes Introduction: Infectious
More informationProper Slide Preparation
Hematology Essentials: A Foundation for WBC Review Using Case Studies Christine Hinz, MS, MLS(ASCP) CM Proper Slide Preparation smooth, homogenous film 1/2 to 3/4 the slide length straight feather edge
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More information2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228
2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood
More informationEDUCATIONAL COMMENTARY DISTINGUISHING MORPHOLOGIC LOOK-ALIKES
EDUCATIONAL COMMENTARY DISTINGUISHING MORPHOLOGIC LOOK-ALIKES Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationHEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE
Log Out Help current login :lcytryn@montefiore.org HEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE Lawrence Cytryn, M.D. - Course Director 1998 Edward Burns, M.D. Images used by permission within AECOM
More informationFormation of Blood Cells
Hematopoiesis Lecture Objectives Name organs responsible for hematopoiesis in the fetus. List the developmental stages of hematopoiesis both prenatally and postnatally. Outline the major steps of post
More informationLymphoma Tumor Board Quiz! Laboratory Hematology: Basic Cell Morphology
Lymphoma Tumor Board Quiz! Laboratory Hematology: Basic Cell Morphology CABOT RINGS Cabot rings in a patient with hemolytic anemia. Cabot ring (red arrow) and Howell-Jolly body (blue arrow). Observed in
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationDifferential Blood Smear H3
Verein für Association pour le Associazione per il medizinische Qualitätskontrolle contrôle de qualité médical controllo di qualità medico Report Differential Blood Smear H3 MQ 2015-4 MQ, Institut für
More informationEDUCATIONAL COMMENTARY MORPHOLOGIC ABNORMALITIES IN LEUKOCYTES
EDUCATIONAL COMMENTARY MORPHOLOGIC ABNORMALITIES IN LEUKOCYTES Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationHISTOLOGY VIRTUAL LABORATORY BLOOD AND LYMPHATICS SYSTEM
HISTOLOGY VIRTUAL LABORATORY BLOOD AND LYMPHATICS SYSTEM Login: http://histopath.westernu.edu Histology Atlas AND Virtual Histology links. I. HEMATOLOGY - PERIPHERAL BLOOD Purpose: To be able to identify
More informationNotes for the 2 nd histology lab
Notes for the 2 nd histology lab Note : Please refer to the slides and see the morphological characteristics of each cell, as the practical exam will be in the form of figures. SLIDE #2 Erythropoiesis
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationEDUCATIONAL COMMENTARY BLOOD CELL IDENTIFICATION
EDUCATIONAL COMMENTARY BLOOD CELL IDENTIFICATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationCOMPANY OR UNIVERSITY
CONTRIBUTOR NAME Daniel Heinrich, DVM CONTRIBUTOR EMAIL dheinric@umn.edu COAUTHORS Jed Overmann, DVM, DACVP; Davis Seelig DVM, PhD, DACVP & Matthew Sturos, DVM COMPANY OR UNIVERSITY University of Minnesota
More informationSH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL
SH2017-0124 A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL NEGATIVE John R Goodlad 1, Pedro Martin-Cabrera 2, Catherine Cargo 2 1. Department of Pathology, NHS Greater Glasgow & Clyde, QEUH, Glasgow 2. Haematological
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationHematopathology Case Study
www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated
More informationCase Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia
Int J Clin Exp Pathol 2014;7(7):4498-4502 www.ijcep.com /ISSN:1936-2625/IJCEP0000851 Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute
More informationThe Complete Blood Count
The Complete Blood Count (Cartesian Thinking at Its Best) A SEM Image of Normal Human Blood Laurie Larsson February 22, 2010 Anatomy and Philology II Dr. Danil Hammoudi Introduction A complete blood count
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationHematopathology Lab. Third year medical students
Hematopathology Lab Third year medical students Objectives Identify the lesion Know the specific name of the lesion Know associated disease Know relevant pathologic background Spherocytes: appear small,
More informationDifferential Blood Smear H3
Verein für Association pour le Associazione per il medizinische Qualitätskontrolle contrôle de qualité médical controllo di qualità medico Report Differential Blood Smear H3 MQ 2018-1 MQ, Institut für
More informationHematopoie)c System. Kris)ne Kra2s, M.D.
Hematopoie)c System Kris)ne Kra2s, M.D. Hematopoie)c System Lecture Objec)ves Describe the developmental stages of erythropoiesis. Describe the developmental stages of granulopoiesis. Describe the differences
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationHematology 101. Cindy Rogers, MT(ASCP) Diagnostics System Specialist
Hematology 101 Cindy Rogers, MT(ASCP) Diagnostics System Specialist More Acronyms...» CBC» RBC» HGB» HCT» WBC» MPV» PLT» RDW» DIFF» H&H» Complete Blood Count» Red Blood Cell» Hemoglobin» Hematocrit» White
More informationOriginal article. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy
Annals ofoncology 8: 7-24, 997. O 997 Kluwer Academic Publishers. Printed in the Netherlands. Original article The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy J.
More informationLeukocyte Disorders. Dr Alauldeen Mudhafar Zubair
Leukocyte Disorders Dr Alauldeen Mudhafar Zubair Composition of blood Specialized connective tissue Blood cells (formed elements) suspended in plasma Blood volume: 5-6 liters (approx 1.5 gal) in males
More informationHENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationLeukocytosis - Some Learning Points
Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful
More informationBlood Cell Identification Graded
Blood Cell Identification Graded Case History The patient is a 20-year-old female with sickle cell disease who presents with bilateral leg pain for 3 days. She is scheduled to have bilateral hip and leg
More informationPeripheral Blood Smear: Diagnostic Clues and Algorithms
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationOrdering Physician CLIENT,CLIENT. Collected REVISED REPORT
HPWET Hematopathology Consultation, MML Embed Client Hematopathology Consult REVISED INAL DIAGNOSIS Interpretation Peripheral blood, bone marrow aspirate and biopsies, bilateral iliac crests: 1. Normocellular
More informationMORPHOLOGY OF BONE MARROW ASPIRATES. Dr.Prasanna N Kumar Head Department of Pathology, Oman Medical College, Oman
MORPHOLOGY OF BONE MARROW ASPIRATES Dr.Prasanna N Kumar Head Department of Pathology, Oman Medical College, Oman BONE MARROW ASPIRATION Sites Sternum Anterior or posterior iliac spines Aspiration from
More informationHematopoiesis Simplified: Part 1 Erythropoiesis
Hematopoiesis Simplified: Part 1 Erythropoiesis Larry Johnson Texas A&M University Hematopoiesis Simplified: Part 1 Erythropoiesis Objectives are to: Identify the developmental cells of erythropoiesis
More informationHemopoiesis and Blood
Hemopoiesis and Blood Blood Cells o o o Erythrocytes Leukocytes Thrombocytes Function o Transport nutrients and wastes throughout the bloodstream, fight foreign antigens and blood coagulation. Location
More informationEDUCATIONAL COMMENTARY MORPHOLOGIC CHANGES IN PERIPHERAL BLOOD CELLS
EDUCATIONAL COMMENTARY MORPHOLOGIC CHANGES IN PERIPHERAL BLOOD CELLS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationADVANCED HAEMATOLOGY BATTLE OF THE BANDS. Dennis B. DeNicola, DVM, PhD, DACVP IDEXX Laboratories, Inc. Westbrook, Maine, USA BACKGROUND
ADVANCED HAEMATOLOGY BATTLE OF THE BANDS Dennis B. DeNicola, DVM, PhD, DACVP IDEXX Laboratories, Inc. Westbrook, Maine, USA BACKGROUND The identification of immature neutrophils (bands, metamyelocytes,
More informationMorfologia normale e patologica
Morfologia normale e patologica Gina Zini Centro di Ricerca ReCAMH Dpt. Ematologia Università Cattolica S. Cuore - Roma EMATOLOGIA DI LABORATORIO: percorsi diagnostici e obiettivi clinici. Milano 11-12
More informationHEAMATOLOGICAL INDICES AND BONE MARROW BIOPSY
HEAMATOLOGICAL INDICES AND BONE MARROW BIOPSY HEMATOCRIT Hematocrit is a measure of the percentage of the total blood volume that is made up by the red blood cells The hematocrit can be determined directly
More informationKathleen Finnegan MS MT(ASCP)SHCM
Kathleen Finnegan MS MT(ASCP)SHCM Discuss the history of hematology automation and digital differentials. Discuss the HemoFAXS Hematology Analysis System by Tissue Gnostics. Review automated microscopy
More informationMegakaryocyte or Precursor, Normal
Precursor, Normal SYNONYMS none VITAL STATISTICS size...20-160 µm in diameter N:C ratio...varible, depending on maturation of cell; early forms have a high N:C rato which decreases as cell matures and
More information3. Blood Cell Histograms:
LECTURE MODULE 6c: ELECTRONIC CELL COUNTING PART III 3. Blood Cell Histograms: a. The Coulter cell counters today provides size distributions of the cellular content: 1) volume given in µm 3 or fl vs relative
More informationBlood Cell Identification: 2011-B Mailing: Acute Myeloid Leukemia (AML)
Please Note: To view the Figures and Images contained within this education activity in color, access the electronic version of the reading. CASE HISTORY This peripheral blood smear is from a 51-year-old
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationYear 2003 Paper two: Questions supplied by Tricia
QUESTION 65 A 36-year-old man presents in a post-ictal state after an observed generalised seizure. Full blood investigation shows: haemoglobin 0 g/l [128-175] mean corpuscular volume (MCV) 106 fl [80-7]
More informationBlood Cell Identification Graded
Blood Cell Identification Graded Case History A 51-year-old female presented with dyspnea on exertion. Laboratory results were as follows: WBC=5.5 X 10 9 /L; Hgb=4.2 g/dl; Hct=13.9%; MCV=78.7fL; RDW=30;
More informationCollect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationBlood Cell Identification Graded
Blood Cell Identification Graded Case History An 11-year-old girl presented to the emergency room with wheezing and was diagnosed as having asthma. Her CBC showed WBC = 12.5 x 10 9 /L; Hgb = 12.4g/dL;
More informationLeukocytes and Platelets
Bởi: OpenStaxCollege The leukocyte, commonly known as a white blood cell (or WBC), is a major component of the body s defenses against disease. Leukocytes protect the body against invading microorganisms
More informationDEPARTMENT OF PHYSIOLOGY
UNIVERSITY OF MEDICAL SCIENCES, ONDO DEPARTMENT OF PHYSIOLOGY BLOOD AND BODY FLUID PHYSIOLOGY LECTURER: MR A.O. AKINOLA OBJECTIVES Leukopoiesis Thrombopoiesis Leukopoiesis and Lymphopoiesis White blood
More informationCase 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationDifferential Blood Smear H3
Verein für Association pour le Associazione per il medizinische Qualitätskontrolle contrôle de qualité médical controllo di qualità medico Report Differential Blood Smear H3 MQ 2014-2 MQ, Institut für
More informationBlood. Kris*ne Kra.s, M.D.
Blood Kris*ne Kra.s, M.D. The most beau*ful thing we can experience is the mysterious. It is the source of all true art and science. - Albert Einstein Blood Lecture Objec*ves Be able to iden*fy and
More informationEvaluation of Bone Marrow Biopsies and Aspirates ANNA PORWIT DEPARTMENT OF PATHOLOGY, LUND UNIVERSITY
Evaluation of Bone Marrow Biopsies and Aspirates ANNA PORWIT DEPARTMENT OF PATHOLOGY, LUND UNIVERSITY DISCLOSURES NONE Learning objectives To review the rules of BMA evaluation To review the main issues
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationBlood DLC, Retic count, PCV, Hb and ESR. Dr. Tamara Alqudah
Blood DLC, Retic count, PCV, Hb and ESR Dr. Tamara Alqudah Differential Leukocyte Count (DLC) There are 5 main types of WBCs: 1. Neutrophils: 40-80% 2. Eosinophils: 1-6 % 3. Basophils: < 1-2% 4. Lymphocytes:
More informationDoes Morphology Matter in 2017
Does Morphology Matter in 2017 ISLH May 2017 Kathryn Foucar Distinguished Professor Emerita kfoucar@salud.unm.edu Objectives Recognize unique RBC and WBC abnormalities in non-neoplastic disorders Learn
More informationIntroduction to Haematology. Prof Roger Pool Department of Haematology University of Pretoria
Introduction to Haematology Prof Roger Pool Department of Haematology University of Pretoria Suggested reading Haematology at a Glance Atul Mehta & Victor Hoffbrand Second Edition Published by Blackwell
More informationBlood & Blood Formation
Module IB Blood & Blood Formation Histology and Embryology Martin Špaček, MD (m.spacek@centrum.cz) http://www.lf3.cuni.cz/histologie Approximately 7% of a person's weight is blood (about 5 L) Blood consists
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم WBCs disorders *Slide 2: - we will focus on the disorders that are related to the # of WBCs - in children the # of lymphocyte is more than it in adults,sometimes more than neutrophils
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationEHE1-16 Participants Identification No. % Evaluation
Cell Identification EHE1-16 Participants Identification No. % Evaluation Blast cell 154 90.1 Educational Lymphocyte 4 2.3 Educational Lymphocyte, reactive 1 0.6 Educational Lymphoma cell (malignant) 1
More informationFull Blood Count analysis Is a 3 part-diff good enough? Dr Marion Münster, Sysmex South Africa
Full Blood Count analysis Is a 3 part-diff good enough? Dr Marion Münster, Sysmex South Africa The Role of the FBC in clinical decision making History Examination Investigations Decision 70% FBC Laboratory
More informationWBCs Disorders. Dr. Nabila Hamdi MD, PhD
WBCs Disorders Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features and
More informationAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia Terri Boyer 17 th October 2006 Overview Disease information: Aetiology of ALL proposed theory, contributing factors Symptoms Complications Diagnostic approaches - morphology
More informationContinuing Education Questions
FOCUS: INTERPRETING THE COMPLETE BLOOD COUNT Continuing Education Questions SUMMER 2017 1. A methodical approach to CBC interpretation that is aimed at medical laboratory professionals differs from one
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationBlood Cells Med Terms Quiz
Blood Cells Med Terms Quiz Question Prompt: 1 Mononuclear white blood cells (agranulocyte) formed in lymph tissue, also a phagocyte and a precursor of macrophages are leukocytes. True False Question Prompt:
More informationr). SUPPLEMENTARY/SECOND OPPORTUNITY EXAMINATION PAPER nnmlbih UNIVERSITY Sophia Blaauw INSTRUCTIONS FACULTY OF HEALTH AND APPLIED SCIENCES
r). nnmlbih UNIVERSITY OF SCIEFICE nnd TECHNOLOGY FACULTY OF HEALTH AND APPLIED SCIENCES DEPARTMENT OF HEALTH SCIENCES QUALIFICATION: BACHELOR OF MEDICAL LABORATORY SCIENCES QUALIFICATION CODE: 08BMLS
More informationDetection and Classification of Acute Leukemia by the Coulter STKS Hematology Analyzer
HEMATOPATHOLOGY Detection and Classification of Acute Leukemia by the Coulter STKS Hematology Analyzer JAMES D. HOYER, MD, 1 CATHERINE P. FISHER, MD, 1 VICKI M. SOPPA, BS, 1 KAY L. LANTIS, SH, MT(ASCP),
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationInterpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired
Interpreting the CBC Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired The CBC 3 Cell Lines RBCs WBCs Platelets Assess general health Make
More informationDifferentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia"
Differentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia" Hoelzer, D.,l, Harriss, E. B.l, Kurrle, E.l, Schmücker, H.l, Hellriegel,
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationHematopoiesis. BHS Liège 27/1/2012. Dr Sonet Anne UCL Mont-Godinne
Hematopoiesis BHS Liège 27/1/2012 Dr Sonet Anne UCL Mont-Godinne Hematopoiesis: definition = all the phenomenons to produce blood cells Leukocytes = White Blood Cells Polynuclear = Granulocytes Platelet
More informationHematopathology Case Study
Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An
More informationCase Presentation. Attilio Orazi, MD
Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia
More information4. TEXTBOOK: ABUL K. ABBAS. ANDREW H. LICHTMAN. CELLULAR AND MOLECULAR IMMUNOLOGY. 5 TH EDITION. Chapter 2. pg
LECTURE: 03 Title: CELLS INVOLVED IN THE IMMUNE RESPONSE LEARNING OBJECTIVES: The student should be able to: Identify the organs where the process of the blood formation occurs. Identify the main cell
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More informationAgriculture, Romania 2 Municipal Clinical Emergency Hospital from Timisoara, Gheorghe Dima Street, no. 5, Romania
MORPHOLOGICAL AND CHEMICAL CHANGES IN BLOOD CELLS IN ACUTE LEUKAEMIA IN HUMANS NOTE 2. MORPHOLOGICAL CHANGES OF FIGURATIVE ELEMENTS BLOOD AND BONE MARROW IN PATIENTS WITH ACUTE LEUKAEMIA SUSPICION Olga-Alina
More information